Umirolimus - Biosensors International
Alternative Names: A9; AXXESS; Ba9; BioFreedom; Biolimus A9 (BA9); Biolimus A9-drug-eluting stent; Biolimus-A-9; BioMatrix; BioMatrix Flex; BioMatrix NeoFlex; BMX-J; Custom NX; Nobori; TRM-986Latest Information Update: 07 Nov 2022
At a glance
- Originator Biosensors International Pte Ltd
- Developer Biosensors International Group; Terumo
- Class Macrolides
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Coronary artery restenosis
- No development reported Coronary artery disease
Most Recent Events
- 07 Oct 2022 Biosensors Europe completes a clinical trial for Coronary artery restenosis in Switzerland and France(Intracoronary) (NCT03118895)
- 28 Feb 2022 No recent reports of development identified for clinical-Phase-Unknown development in Coronary artery disease in Spain (Intracoronary)
- 04 Feb 2020 Phase II development is ongoing for Coronary artery restenosis in Switzerland (NCT03118895)